Nov 14, 2024 · We are Inhibikase Therapeutics, a pharmaceutical company innovating small-molecule kinase inhibitor therapeutics to treat Parkinson’s disease, Parkinson’s-related …

1 day ago · Inhibikase’s stock price declined more than 19% in after-hours trading at $2.26 per share, down from $2.80 at the previous close. Risvodetinib’s discontinuation highlights the …

1 day ago · Inhibikase Therapeutics announced results from a Phase 2 trial of its Parkinson’s disease drug, risvodetinib, a selective inhibitor of the non-receptor Abelson tyrosine kinases, in …

2 days ago · Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out …

1 day ago · Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic options” for the med after it came up short in the efficacy …

We have developed a platform prodrug technology that adds a small linker to a known or novel kinase inhibitor and suppresses on-dosing side effects common to drugs in this class, …

Inhibikase Therapeutics develops treatments that seek to intervene in neurodegeneration where disease begins. Our treatments flow from a novel understanding of the etiology—cause or set …

May 16, 2023 · Inhibikase's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the …

8 hours ago · Clinical-stage USA-based drug developer Inhibikase Therapeutics (Nasdaq: IKT) saw its shares tumble more than 31% to $1.92, after is revealed that it is pausing development …

Mar 20, 2024 · At the 2024 AD/PD Meeting, held March 5-9, in Lisbon, Portugal, Inhibikase presented an update on its phase 2 study, Trial 201 (NCT05424276), assessing its …